
Asundexian’s FDA Approval Opens Doors for Future Antithrombotic Therapies
Mike Sharma, MD, MSc, discusses how asundexian’s approval revolutionizes secondary stroke prevention – and may provide a pathway to treat many more conditions.
Asundexian has officially become the first factor XIa (FXIa) inhibitor to receive approval from the
Announced by parent company Bayer on November 9, 2026, the approval is a groundbreaking opportunity for both this patient population and the therapeutic category, as FXIa inhibition has opened up a wholly new treatment pathway for a variety of cardiovascular diseases. In an interview with HCPLive, Mike Sharma, MD, MSc, director of the stroke program at Hamilton Health Sciences and Michael G. DeGroote Chair in Stroke Prevention at McMaster University, discusses the implications of this approval for the future of antithrombotic development.
“In spite of a lot of efforts to improve an antithrombotic therapy for these patients, we hadn’t succeeded until now,” Sharma told HCPLive in an exclusive interview. “Other attempts have failed either because the treatment was ineffective, or it was associated with too much bleeding, or both. I think that this is really a paradigm-changing, practice-influencing result that we’ve had.”
Asundexian’s new approval is based on the results from OCEANIC-STROKE, a multicenter, international, randomized, placebo-controlled, parallel group, double-blind, event-driven phase 3 trial comparing asundexian’s efficacy on top of antiplatelet therapy to placebo in the prevention of second ischemic stroke. Patients were enrolled in the trial if they had a prior non-cardioembolic stroke or high-risk TIA and had systemic or cerebrovascular atherosclerosis or acute non-lacunar infarct. Patients with an index stroke following procedures or strokes due to other causes, among other criteria, were excluded.2
Patients were randomly assigned to receive either asundexian or placebo once daily. The primary endpoints were time to first occurrence of ischemic stroke up to 31 months and time to first occurrence of International Society on Thrombosis and Hemostasis (ISTH) major bleeding up to 31 months. Secondary endpoints included time to first occurrence of all strokes, time to first occurrence of a composite of cardiovascular death or myocardial infarction, and time to first occurrence of all-cause mortality, among others.2
A total of 12,327 patients were randomized into the trial, with 6162 receiving asundexian and 6165 receiving placebo. Over a median follow-up of 19 months, ischemic stroke incidence was lower in the asundexian group versus the placebo group (6.2% vs 8.4%; cause-specific HR, 0.74; 95% CI, 0.65 to 0.84; P <.001). Major bleeding, meanwhile, was similar in both arms (1.9% and 1.7%, respectively; cause-specific HR, 1.1; 95% CI, 0.85 to 1.44). Adverse events occurred in 69.3% of the asundexian arm and 70.1% in the placebo arm, but serious adverse events were 19.2% and 19.5%, respectively.3
Ultimately, Sharma, who was among the investigators on this trial, determined that asundexian successfully reduced the risk of recurrent ischemic stroke without increasing bleeding. This represents a substantial step forward for antithrombotic therapy, particularly given the increased rates of bleeding that typically accompany these medications. Asundexian, therefore, provides clinicians with a safer alternative to treat patients at risk of secondary strokes, and potentially a variety of other conditions as well.
“The amazing results we’ve seen in OCEANIC really suggest that we should explore other conditions where this might be helpful,” Sharma said. “The one thing that we have not seen before is a clinical effect on thrombosis without an increase in bleeding. Now that we have that, it lets us think about treating larger numbers of people.”
References
FDA approves first factor XIa inhibitor to help prevent stroke in certain adults at high risk. News release. FDA. November 9, 2026. Accessed November 9, 2026.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk Bayer. A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE). ClinicalTrials.gov Identifier: NCT05686070. Updated November 12, 2025. Accessed November 16, 2026.
https://clinicaltrials.gov/study/NCT05686070 Sharma M, Dong Q, Hirano T, et al. Asundexian for secondary stroke prevention. N Engl J Med. 2026;394(15):1467-1479.
doi:10.1056/NEJMoa2513880
Related to this article








